OKYO Pharma’s Chief Medical Officer Acquires 20,000 Shares at $1.40 Ahead of Phase 3 Trial Launch

Executive Share Purchase Highlights Confidence in OKYO’s Neuropathic Corneal Pain Program

Dr. Flavio Mantelli’s purchase of 20,000 shares at $1.40 each represents a meaningful personal investment by OKYO Pharma’s senior clinical leader. Insider buying in clinical-stage biotech companies often signals executive confidence in the scientific validity and commercial potential of the development pipeline. This transaction took place on the Nasdaq Capital Market, where OKYO’s shares are publicly traded.

OKYO Pharma is at a pivotal stage in its clinical development strategy. By acquiring these shares, Dr. Mantelli aligns his financial interests with those of shareholders as the company mobilizes resources for its most significant clinical trial to date. The $1.40 purchase price provides a valuation reference at announcement, although immediate market reaction remains unclear.

OKYO’s Specialized Pipeline Focused on Neuropathic Corneal Pain

OKYO Pharma Limited specializes in investigational therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases. The company concentrates on this underserved patient population suffering from corneal nerve damage and related ocular pain, positioning itself within the ophthalmology and rare disease sectors. This focus targets a niche with high unmet medical needs and limited competition, offering substantial commercial potential.

Neuropathic corneal pain is characterized by corneal nerve dysfunction causing severe, debilitating pain that impairs quality of life. The anterior segment includes the cornea, iris, lens, and adjacent tissues. OKYO’s focus on diseases affecting this region addresses conditions impacting vision and comfort but outside common ophthalmic markets like age-related macular degeneration or diabetic retinopathy. This strategic niche offers opportunities for impactful clinical and commercial success.

Details on Urcosimod Phase 3 Trial: Scope, Timeline, and Enrollment

OKYO Pharma plans to initiate a global Phase 3 pivotal trial in the second half of 2026 for its lead therapy, urcosimod. The trial will enroll approximately 111 patients to evaluate a single-dose regimen for neuropathic corneal pain treatment. Phase 3 trials are the final clinical step before regulatory approval by agencies such as the FDA and EMA, making this trial critical to OKYO’s commercial future.

The single-dose regimen focus indicates prior clinical data supporting favorable pharmacokinetics and safety. If approved, this approach could offer practical benefits over multi-dose therapies for patients and healthcare providers. The moderate trial size reflects the specialized patient population with acute unmet needs.

Nasdaq Capital Market Listing and Its Strategic Importance

OKYO Pharma’s ordinary shares trade on the Nasdaq Capital Market under the ticker OKYO. Listing on Nasdaq provides access to institutional and retail investors, enhances visibility, and facilitates future capital raises. The Nasdaq Capital Market supports emerging growth companies like OKYO that may not meet higher-tier listing standards.

While public listing imposes regulatory and reporting responsibilities, it offers strategic advantages for funding expensive Phase 3 trials and providing liquidity to employees and early investors. Being listed also increases transparency, potentially boosting credibility with partners, investors, and patients.

Clinical-Stage Status and Regulatory Approval Pathway

As a clinical-stage company, OKYO Pharma has not yet secured regulatory approval for any therapy. Its value depends on the scientific rationale, clinical data quality, and execution expertise. Clinical-stage firms carry higher risks than commercial-stage companies due to lack of marketed products and real-world efficacy validation.

Advancing from clinical to commercial stage requires successful Phase 3 trial completion, regulatory submission (e.g., New Drug Application in the U.S.), and approval. OKYO’s Phase 3 urcosimod trial is a critical milestone. Positive results would support regulatory filings, while failure could severely impact the program’s prospects. This trial will be the main driver of news and value over the next few years.

Senior Leadership’s Scientific Expertise and Oversight

Dr. Flavio Mantelli, MD, PhD, as Chief Medical Officer, leads clinical strategy, trial design, regulatory engagement, and scientific oversight at OKYO Pharma. This role is vital in ensuring rigorous, statistically sound, and regulatory-aligned clinical development. His personal investment at $1.40 per share signals confidence in the company’s scientific and clinical approach.

By acquiring 20,000 shares, Dr. Mantelli becomes a significant stakeholder, reinforcing leadership’s belief in the neuropathic corneal pain program’s potential. Investors often consider the experience and reputation of senior clinical executives when assessing biotech development credibility.

Addressing Unmet Needs in Anterior Segment Eye Diseases

OKYO’s focus on anterior segment eye diseases, especially neuropathic corneal pain, targets a segment with limited effective treatments. Causes include corneal scarring, refractive surgery, diabetes, infection, or idiopathic origins. Patients suffer severe ocular pain resistant to conventional therapies, impacting quality of life and productivity.

This unmet need creates a market opportunity for effective, well-tolerated therapies. Regulatory pathways for rare diseases often offer expedited reviews and market exclusivity, benefiting companies developing novel treatments. If urcosimod proves safe and effective, OKYO could fill a significant clinical gap and capture commercial value.

Risks Specific to OKYO’s Clinical Development Stage

OKYO Pharma faces scientific, clinical, regulatory, and financial risks typical of clinical-stage biopharmaceutical companies. Urcosimod may fail to demonstrate efficacy or safety in Phase 3, which could lead to program termination, value loss, and financial hardship. Regulatory approval is uncertain, and trials can yield unexpected outcomes.

Capital availability is another risk, as ongoing funding is needed for trials, regulatory submissions, and operations. Unexpected costs or unfavorable market conditions could create liquidity challenges. Additionally, competitive threats exist if alternative therapies outperform urcosimod.

Phase 3 Trial Initiation Timeline and Market Outlook for H2 2026

OKYO plans to start the global Phase 3 trial in the second half of 2026, indicating progress in protocol finalization, site activation, regulatory interactions, and recruitment planning. Trial initiation is a key milestone attracting investor and analyst attention, potentially boosting market sentiment if the design and infrastructure are strong.

Investors will monitor enrollment speed, recruitment, and early safety data. Delays or safety concerns could negatively affect sentiment, while smooth progress and favorable safety profiles may support share price. Trial completion and data readout expected in 2027 or later will be major inflection points.

Corporate Governance and Insider Transaction Transparency

Disclosure of Dr. Mantelli’s share purchase exemplifies insider transaction reporting required by securities regulations in the U.S., U.K., and elsewhere. Such transparency provides market participants insight into insider confidence or concerns, promoting market efficiency and protecting investors.

OKYO’s official announcement of this insider purchase reflects its commitment to compliance and transparency. While insider buying signals confidence, it should be considered alongside other factors when making investment decisions.